Peramivir - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for peramivir and what is the scope of freedom to operate?
Peramivir
is the generic ingredient in one branded drug marketed by Biocryst and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Peramivir has forty-two patent family members in fourteen countries.
There is one drug master file entry for peramivir. One supplier is listed for this compound.
Summary for peramivir
| International Patents: | 42 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 146 |
| Clinical Trials: | 16 |
| Patent Applications: | 2,587 |
| What excipients (inactive ingredients) are in peramivir? | peramivir excipients list |
| DailyMed Link: | peramivir at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for peramivir
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for peramivir
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Oxford | Phase 2 |
| Hoffmann-La Roche | Phase 3 |
| Department of Health and Human Services | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for peramivir
US Patents and Regulatory Information for peramivir
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for peramivir
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for peramivir
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Biocryst | Alpivab | peramivir | EMEA/H/C/004299 Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. |
Withdrawn | no | no | no | 2018-04-13 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for peramivir
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2649090 | TRAITEMENTS ANTIVIRAUX INTRAMUSCULAIRES (INTRAMUSCULAR ANTIVIRAL TREATMENTS) | ⤷ Sign Up |
| Hong Kong | 1212250 | 抗病毒化合物、包含該化合物的劑型及其用途 (ANTIVIRAL COMPOUNDS, UNIT DOSAGE FORM COMPRISING SAID COMPOUNDS AND USE THEREOF) | ⤷ Sign Up |
| Malaysia | 166063 | INTRAVENOUS ANTIVIRAL TREATMENTS | ⤷ Sign Up |
| China | 101420948 | Intramuscular antiviral treatments | ⤷ Sign Up |
| South Korea | 20210135632 | 정맥내 항바이러스 치료 (INTRAVENOUS ANTIVIRAL TREATMENTS) | ⤷ Sign Up |
| South Korea | 20080096829 | INTRAVENOUS ANTIVIRAL TREATMENTS | ⤷ Sign Up |
| Eurasian Patent Organization | 200870430 | ВНУТРИМЫШЕЧНЫЕ АНТИВИРУСНЫЕ СПОСОБЫ ЛЕЧЕНИЯ | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
